anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a preparation for external use for the skin excellent in moisture retaining effect, capable of strongly adhering to the skin and excellent in water resistance and durable effects by combining an acidic heteropolysaccharide with a sol of a specific metal. SOLUTION: In this preparation for external use for the skin, both (A) an acidic heteropolysaccharide and (B) sol of a superfine metal oxide are used. As the acidic heteropolysaccharide, the one derived from a callus of a plant belonging to the genus Polianthes L. or from a callus of Polianthes tuberosa L. is preferable. As the sol of the superfine metal oxide, an aqueous sol in which the superfine metal oxide particles having 0.005-0.1μm average size are dispersed is preferable. The aqueous sol preferably contains 5-30wt.% dispersed superfine metal oxide particles. As the metal oxide, titanium oxide or silicon oxide is preferable. The weight ratio of the component A to an active concentration B' of the metal oxide in the sol is preferably A/B' of (0.2/0.001)-(0.2/4). This preparation for external use for the skin is good in feeling in use.
In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration. A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above ,basic principles of health education and in communication skills through a 2 days training workshop. The trained head teachers and heath teachers will in turn, deliver the messages to the children through face to face interactions during school assemblies, twice a week.
The present invention concerns materials and methods relating to the expression of genes. In particular, it relates to the expression of multiple gene products as a single cistron. The invention is achieved by constructing a nucleic acid construct comprising a first sequence encoding a first polypeptide (such as a protein subunit) and a second sequence encoding a second polypeptide (a further protein subunit), said first and second sequences being separated by a linker sequence encoding an endoprotease cleavage site. Once expressed as a single fusion protein it can be cleaved and processed into its constituent, biologically active, first and second polypeptides. The invention has particular implications with regard to expression of proteins that have multiple subunits (e.g. IL-12) that require expression of the independent subunits at equimolar amounts.
BACKGROUND: Social frailty (SF) is associated with multiple adverse health outcomes, yet there has been an inadequate focus on social frailty. The convoy model portrays the social networks through the perspective of the life course, thus providing a framework to explain the occurrence of social frailty. This study aimd to figure out the prevalence of social frailty and loneliness among community-dwelling older adults and to explore their correlations based on convoy model.
METHODS: This was a cross-sectional study, and 295 older adults from 10 communities of Zhengzhou in Henan Province participated in the study. Social frailty and loneliness were assessed separately with the Social Frailty Scale and University of California at Los Angeles-Loneliness Scale. The scores of social frailty of the older adults in different characteristic communities were compared by independent sample t-test and single factor analysis of variance. The influencing factors of social frailty were analysed by multiple stepwise linear regression and the structural equation model. The correlation between social frailty and loneliness was analysed by Pearson correlation analysis.
RESULTS: The total scores of social frailty and loneliness of the older adults in the community were (2.09 ± 1.53) and (43.19 ± 8.91), respectively. There was a moderate positive correlation between social frailty and loneliness (r = 0.621, P < 0.01). The results of multiple stepwise linear regression analysis showed that age, living styles, balance of payments, and loneliness were the main influencing factors of the social frailty of older adults in the community (F = 27.180, P < 0.001). The structural equation model of social frailty fitted well (χ2 = 47.292, df = 26, χ2/df = 1.819, P = 0.007; RMSEA = 0.053, 95%CI (0.028, 0.076), P = 0.359; GFI = 0.971; AGFI = 0.939; NFI = 0.904; IFI = 0.955; TLI = 0.918; CFI = 0.953; SRMR = 0.0466).
CONCLUSIONS: The convoy model had certain applicability in explanation of the relationship between loneliness and social frailty among older adults in community. The incidence of social frailty among the older adults in the community was high, and loneliness was at a medium level. It is necessary to strengthen the intervention of social frailty and loneliness of the older adults in the community, improve the quality of life of the older adults, and promote the development of healthy aging.
Nasal spray of Oxytocin 12 International Unit (12IU) liquid solution as 2 puffs of daily dose (every morning) for 3 weeks. fMRI scan pre and post administration.
This will be a randomized, controlled trial of 300 women with a diagnosis of preeclampsia at any point in their current pregnancy or immediately postpartum. Immediately postpartum is defined as preeclampsia diagnosed after delivery but prior to discharge from the hospital. The diagnosis of preeclampsia will be made using standardized definitions by the American College of Obstetrics and Gynecology. Preeclampsia is diagnosed with new-onset hypertension of blood pressure of greater than or equal to 140 systolic blood pressure or greater than or equal to 90 diastolic blood pressure recorded twice at least four hours apart AND proteinuria, defined as 300mg of protein in a 24hour urine collection or a protein/creatinine ratio of 0.3. If the above blood pressure criteria are met and there is not proteinuria, preeclampsia can still be diagnosed if there is thrombocytopenia with platelet count of less than 100,000, renal insufficiency with creatinine of greater than 1.1 or twice the patient's individual baseline, impaired liver function with AST or ALT twice normal or epigastric/right upper quadrant pain, pulmonary edema, new-onset headache unresponsive to medication, or visual disturbance. All of these findings should not be explained by an alternative diagnosis.

Women will be consented and randomized at the time of their diagnosis, within 96 hours of their delivery. The patients randomized to the treatment group will have an antihypertensive medication prescribed to them. The specific medication will be either labetalol, nifedipine or hydralazine based on allergies and clinically appropriateness of the medication. The patient will be instructed on the dosing, timing, and possible adverse effects. All subject's blood pressures will be monitored per standard postpartum protocols. As per standard practice, all patients with preeclampsia will be asked to return at 7-10 days for a blood pressure check and then again at 6 weeks for a complete postpartum assessment.

Consent of patients, review of blood pressures, data collection and storage, and statistical analysis will be performed at the Medical College of Wisconsin (MCW) through the Maternal Fetal medicine department. Women will be allowed to continue routine antenatal, intrapartum and postpartum care with their primary obstetrician. The research team will follow enrolled patients through the 6-week postpartum follow up.
Phenol-formaldehyde resins suitable for dentures are made by causing phenol to react with an excess of aqueous formaldehyde over equimolecular parts in the presence of a basic condensing agent, acidifying the reaction mass prior to reaching a gelation stage with oxalic acid or an organic acid of substantially equivalent strength and thereafter dehydrating the reaction product by evaporation of the resulting mixture of resin, water and insoluble salts.  In an example, phenol is heated with formaldehyde (40 per cent) in presence of sodium carbonate for about an hour, acidified with oxalic acid and the mixture dehydrated.  Part of the excess of formaldehyde may be added after the acidification step.  In the manufacture of dentures, strips of the material are baked in the mould for one hour under a pressure of 35 lbs. per square inch at 135 DEG  C.  The composition may also be used for cameos, trinkets, buttons and handles and can be dyed or pigmented.  Specification 129,993, [Class 2 (iii), Dyes &c.], is referred to.ALSO:Cameos, trinkets, buttons and handles are made by moulding a special phenol-aldehyde resin.  The mould is packed with strips of the resin, closed, and baked for about one hour under a pressure of about 35 lbs. per square inch and at a temperature of 135 DEG  C. After cooling, the mould is opened and the product removed.ALSO:Dentures are made by baking a special phenolaldehyde composition in a mould for one hour under a pressure of 35 lbs. per square inch at 135 DEG  C.  The composition may contain pigments or dyes.
<P>PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition for treating inflammatory bowel diseases in a human.  <P>SOLUTION: This composition contains zinc acexamate, namely, zinc N-acetyl-6-aminohexanoate. The zinc acexamate is solely used as an active ingredient, or combinedly used together with another active ingredient. The pharmaceutical composition is administered perorally and/or rectally, and preferably administered in a unit administration form containing 20-500 mg of the zinc acexamate. The composition is effective for the inflammatory bowel diseases and/or Crohn's disease.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The prevalence of women making an irrational decision will be compared to the participation rate in the Danish screening program. The study population will consist of a random sample of women aged 44-49. Similar to the American study, two types of information will be compared (detailed vs. non-detailed information about the harms of screening). Participants will be randomised to one of two information groups. Based on the American study, it is assumed that the willingness to participate in the hypothetical screening program will be 40 percent. To achieve the desired precision in this study, a standard error of 2.5 percent is required corresponding to a confidence interval spanning approximately 35-45 percent. This will require 384 women in each group, corresponding to a total study population of 768. The survey will be sent electronically (using "e-Boks") with a link to access the online survey trial. The survey will consist of screening and cancer related questions as well as questions on age, education, and health literacy. Five questions on appraisal of health information from the Health Literacy Questionnaire will also be included. After the data collection, data will be linked to data on income, residence, civil status, education, breast cancer diagnosis, and information on whether a participant is immigrant, descendent or of Danish origin.

The original plan for the main analysis was to compare the two groups of women randomized to different information groups (detailed vs. non-detailed information about the harms of screening). However, due to lower participation rate and therefore smaller sample size than expected, information group was disregarded in the main analysis. The two groups will still be compared in a secondary analysis. This decision was made before getting access to data from the questionnaire.
A  Bacillus  strain characterized by (i): sensitivity for ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline and chloramphenicol antimicrobial activity against  E. coli  and  Clostridium perfringens ; and (iii) a sporulation percentage of at least 80 when measured after 2 days of incubation. The invention further relates to a method for selecting such strains. Many of the identified strains according to the invention are of the species  Bacillus amyloliquefaciens . Some of the  Bacillus amyloliquefaciens  were further identified as  Bacillus amyloliquefaciens  subsp.  amyloliquefaciens  whereas others were identified as  amyloliquefaciens  subsp  plantarum . A  Bacillus  strain of the invention may be used as a feed additive to animal feed where it has a probiotic effect.
Adenoid hypertrophy is a common condition in children causing symptoms such as mouth breathing, nasal discharge, snoring, sleep apnea, and hypo nasal speech. It also plays a role in the pathogenesis of rhinosinusitis, recurrent otitis media, and otitis media with effusion. Currently, adenoidectomy is one of the most commonly performed pediatric surgical procedures worldwide. Although there is still poor evidence in the literature, recurrent upper respiratory infections, otitis media with effusion, and obstructive sleep apnea syndrome are considered to be the main indications of adenoidectomy . Conventional curettage adenoidectomy (CCA) is a widely adopted method for over a hundred years. Conventional curettage adenoidectomy is performed blindly via adenoid curette; this may be associated with residual adenoid tissue existence and increased postoperative morbidity including, Eustachian tube dysfunction, inadvertent injury to peripheral tissue and postoperative bleeding . An ideal adenoidectomy technique should be safe, quick, easy, and provide decreased postoperative complication and morbidity .Recently Adenoidectomy can be carried out with several techniques such as electrocautery, bipolar coagulation, radiofrequency ablation, and coblation techniques .

Eustachian tube dis function (ETD) can develop due to surgical trauma , edema in surrounding tissues and clots in early period following adenoidectomy surgery performed with curettage technique .
BACKGROUND: Rhabdomyosarcoma (RMS) is a rare malignancy and the most common soft tissue sarcoma in children. Vasculogenic mimicry (VM) is a novel tumor microcirculation model different from traditional tumor angiogenesis, which does not rely on endothelial cells to provide sufficient blood supply for tumor growth. In recent years, VM has been confirmed to be closely associated with tumor progression. However, the ability of RMS to form VM has not yet been reported.
METHODS: Immunohistochemistry, RT-qPCR and western blot were used to test the expression level of SNAI2 and its clinical significance. The biological function in regulating vasculogenic mimicry and malignant progression of SNAI2 was examined both in vitro and in vivo. Mass spectrometry, co-immunohistochemistry, immunofluorescence staining, and ubiquitin assays were performed to explore the regulatory mechanism of SNAI2.
RESULTS: Our study indicated that SNAI2 was abnormally expressed in patients with RMS and RMS cell lines and promoted the proliferation and metastasis of RMS. Through cell tubule formation experiments, nude mice Matrigel plug experiments, and immunohistochemistry (IHC), we confirmed that RMS can form VM and that SNAI2 promotes the formation of VM. Due to SNAI2 is a transcription factor that is not easily drugged, we used Co-IP combined with mass spectrometry to screen for the SNAI2-binding protein USP7 and TRIM21. USP7 depletion inhibited RMS VM formation, proliferation and metastasis by promoting SNAI2 degradation. We further demonstrated that TRIM21 is expressed at low levels in human RMS tissues and inhibits VM in RMS cells. TRIM21 promotes SNAI2 protein degradation through ubiquitination in the RMS. The deubiquitinase USP7 and E3 ligase TRIM21 function in an antagonistic rather than competitive mode and play a key role in controlling the stability of SNAI2 to determine the VM formation and progression of RMS.
CONCLUSION: Our findings reveal a previously unknown mechanism by which USP7 and TRIM21 balance the level of SNAI2 ubiquitination, determining RMS vasculogenic mimicry, proliferation, and migration. This new mechanism may provide new targeted therapies to inhibit the development of RMS by restoring TRIM21 expression or inhibiting USP7 expression in RMS patients with high SNAI2 protein levels.
During cancer treatment, cachexia, characterized by muscle loss, often occurs, with one of the contributing factors being muscle toxicity caused by anticancer drugs. It affects approximately 80% of patients with cancer, particularly those with digestive organ malignancies. However, effective treatment for this condition remains elusive. Therefore, in this study, we aimed to investigate the therapeutic potential of exosomes in relieving cachexia. Specifically, we examined the exosomes derived from muscle stem cells, which are involved in muscle cell regeneration and their role in controlling anticancer drug-induced muscle toxicity. First, exosomes secreted from myoblasts under depletion conditions were characterized. Exosomes were isolated under serum starvation conditions, displaying an average size of 113 nm and containing typical exosome marker proteins. Furthermore, electron microscopy confirmed their exosomal nature. To confirm the paracrine function of myoblast-derived exosomes (MDEs), a significant increase in cell viability was observed upon their application to myoblasts. No changes were observed in the cell cycle during exosome treatment. However, it was confirmed that the quantity of viable cells increased under serum starvation conditions. This suggests that MDEs possess the function of enhancing myoblast survival and overall cell viability. Cachexia, a prevalent condition in patients with cancer, often manifests as muscle cell depletion induced by anticancer drugs. The potential of MDEs to inhibit cell death induced by anticancer drugs was investigated. The findings revealed that while high concentrations of oxaliplatin and doxorubicin, known to induce cachexia, did not restore cell viability, lower concentrations did. This study suggests that MDEs may have the potential to control cachexia, a common side effect of anticancer drugs, by reducing muscle cell damage induced by anticancer drugs.
The following adverse reactions have been identified during post-approval use of ELIGARD. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure.

Pituitary apoplexy\- During postmarketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a pituitary adenoma was diagnosed with a majority of pituitary apoplexy cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy has presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention has been required.

Nervous System\- Convulsions

Respiratory System\- Interstitial lung disease
In patients who may be susceptible to the intracranial effects of CO2 retention (e.g., those with evidence of increased intracranial pressure or brain tumors), DURAMORPH may reduce respiratory drive, and the resultant CO2 retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with DURAMORPH. DURAMORPH should be used with extreme caution in patients with head injury or increased intracranial pressure. Pupillary changes (miosis) from morphine may obscure the existence, extent and course of intracranial pathology. High doses of neuraxial morphine may produce myoclonic events [see Warnings and Precautions (5.6)]. Clinicians should maintain a high index of suspicion for adverse drug reactions when evaluating altered mental status or movement abnormalities in patients receiving this modality of treatment.

Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of DURAMORPH in patients with impaired consciousness or coma.
Group A will be training group and group B will be control group. Deep breathing exercises will be done as baseline treatment in both groups. Both groups will be assessed with Modified Borg scale, 6-PBRT and Fatigue severity scale at the baseline. The control group patients will perform functional active alternating movements for the upper limbs at home involving three sets with 10 repetitions and a rest interval between 1- and 2-minute.

Intervention will be for 3 times a week or 6 weeks. The treatment group patients will perform upper extremity aerobic exercises by using an arm ergometer under the supervision of a physiotherapist. Training intensity will adjust according to 50 80 % of max HR or intensity of dyspnea to 4 points on modified Borg scale (MBS) for at least 15 45 min, 3 times/week over 6 weeks. This study will measure and record HR by using the heart rate monitor, oxygen saturation (SpO2) by using pulse oximetry and blood pressure, breathing frequency (BF), dyspnea, fatigue, and arm fatigue by using MBS before, during, and after training.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to the levothyroxine sodium-base pharmaceutical composition. Invention describes pharmaceutical composition that comprises levothyroxine sodium, gelatin and carriers as its components being without residues of organic solvents and method for it preparing also. Invention provides stability of the proposed composition. EFFECT: improved preparing method. 8 cl, 3 ex
The invention discloses an HTNV-Gn/Gc specific T cell epitope peptide and an application thereof. The amino acid sequence of the HTNV-Gn/Gc specific T cell epitope peptide is one selected from SEQ ID NO. 1 to SEQ ID NO. 75. The HTNV-Gn/Gc specific T cell epitope peptide comprises CD4<+>T cell epitope and CTL epitope, and can respectively induce CD4<+>T cell and CD8<+>T cell to generate intensive cellular immunologic response and to secrete high-level IFN-gamma. The HTNV-Gn/Gc specific T cell epitope peptide can be used in the preparation of T cell epitope peptide vaccines, and can be used in inducing CD4<+>T cell or cytotoxicity T cell generating epitope peptide specificity. Therefore, the HTNV-Gn/Gc specific T cell epitope peptide has a good exploitation and application prospect in the field of HFRS specific immunotherapy.